Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 97 to 103 of 103 entries
Sorted by: Best Match Show Resources per page
An Overview of Phase 2 Clinical Trial Designs.

International journal of radiation oncology, biology, physics

Torres-Saavedra PA, Winter KA.
PMID: 34363901
Int J Radiat Oncol Biol Phys. 2022 Jan 01;112(1):22-29. doi: 10.1016/j.ijrobp.2021.07.1700. Epub 2021 Aug 04.

Clinical trials are studies to test new treatments in humans. Typically, these treatments are evaluated over several phases to assess their safety and efficacy. Phase 1 trials are designed to evaluate the safety and tolerability of a new treatment,...

Cite
Torres-Saavedra PA, Winter KA. An Overview of Phase 2 Clinical Trial Designs. Int J Radiat Oncol Biol Phys. 2021;112(1):22-29doi: 10.1016/j.ijrobp.2021.07.1700.
Torres-Saavedra, P. A., & Winter, K. A. (2022). An Overview of Phase 2 Clinical Trial Designs. International journal of radiation oncology, biology, physics, 112(1), 22-29. https://doi.org/10.1016/j.ijrobp.2021.07.1700
Torres-Saavedra, Pedro A, and Winter, Kathryn A. "An Overview of Phase 2 Clinical Trial Designs." International journal of radiation oncology, biology, physics vol. 112,1 (2022): 22-29. doi: https://doi.org/10.1016/j.ijrobp.2021.07.1700
Torres-Saavedra PA, Winter KA. An Overview of Phase 2 Clinical Trial Designs. Int J Radiat Oncol Biol Phys. 2022 Jan 01;112(1):22-29. doi: 10.1016/j.ijrobp.2021.07.1700. Epub 2021 Aug 04. PMID: 34363901; PMCID: PMC8688307.
Copy Download .nbib Format: NLM
Quality of Life and Adverse Events: Prognostic Relationships in Long-Term Ovarian Cancer Survival.

Journal of the National Cancer Institute

Wenzel L, Osann K, McKinney C, Cella D, Fulci G, Scroggins MJ, Lankes HA, Wang V, Nephew KP, Maxwell GL, Mok SC, Conrads TP, Miller A, Mannel RS, Gray HJ, Hanjani P, Huh WK, Spirtos N, Leitao MM, Glaser G, Sharma SK, Santin AD, Sperduto P, Lele SB, Burger RA, Monk BJ, Birrer M.
PMID: 33729494
J Natl Cancer Inst. 2021 Oct 01;113(10):1369-1378. doi: 10.1093/jnci/djab034.

BACKGROUND: There is a critical need to identify patient characteristics associated with long-term ovarian cancer survival.METHODS: Quality of life (QOL), measured by the Functional Assessment of Cancer Therapy-Ovarian-Trial Outcome Index (FACT-O-TOI), including physical, functional, and ovarian-specific subscales, was compared...

Cite
Wenzel L, Osann K, McKinney C, et al. Quality of Life and Adverse Events: Prognostic Relationships in Long-Term Ovarian Cancer Survival. J Natl Cancer Inst. 2021;113(10):1369-1378doi: 10.1093/jnci/djab034.
Wenzel, L., Osann, K., McKinney, C., Cella, D., Fulci, G., Scroggins, M. J., Lankes, H. A., Wang, V., Nephew, K. P., Maxwell, G. L., Mok, S. C., Conrads, T. P., Miller, A., Mannel, R. S., Gray, H. J., Hanjani, P., Huh, W. K., Spirtos, N., Leitao, M. M., Glaser, G., Sharma, S. K., Santin, A. D., Sperduto, P., Lele, S. B., Burger, R. A., Monk, B. J., & Birrer, M. (2021). Quality of Life and Adverse Events: Prognostic Relationships in Long-Term Ovarian Cancer Survival. Journal of the National Cancer Institute, 113(10), 1369-1378. https://doi.org/10.1093/jnci/djab034
Wenzel, Lari, et al. "Quality of Life and Adverse Events: Prognostic Relationships in Long-Term Ovarian Cancer Survival." Journal of the National Cancer Institute vol. 113,10 (2021): 1369-1378. doi: https://doi.org/10.1093/jnci/djab034
Wenzel L, Osann K, McKinney C, Cella D, Fulci G, Scroggins MJ, Lankes HA, Wang V, Nephew KP, Maxwell GL, Mok SC, Conrads TP, Miller A, Mannel RS, Gray HJ, Hanjani P, Huh WK, Spirtos N, Leitao MM, Glaser G, Sharma SK, Santin AD, Sperduto P, Lele SB, Burger RA, Monk BJ, Birrer M. Quality of Life and Adverse Events: Prognostic Relationships in Long-Term Ovarian Cancer Survival. J Natl Cancer Inst. 2021 Oct 01;113(10):1369-1378. doi: 10.1093/jnci/djab034. PMID: 33729494; PMCID: PMC8486331.
Copy Download .nbib Format: NLM
A Surgical Window Trial Evaluating Medroxyprogesterone Acetate with or without Entinostat in Patients with Endometrial Cancer and Validation of Biomarkers of Cellular Response.

Clinical cancer research : an official journal of the American Association for Cancer Research

Duska LR, Filiaci VL, Walker JL, Holman LL, Hill EK, Moore RG, Ring KL, Pearl ML, Muller CY, Kushnir CL, Lankes HA, Samuelson MI, Carrick KS, Rajan A, Rodgers WH, Kohn EC, Piekarz R, Leslie KK.
PMID: 33766814
Clin Cancer Res. 2021 May 15;27(10):2734-2741. doi: 10.1158/1078-0432.CCR-20-4618. Epub 2021 Mar 25.

PURPOSE: This surgical window of opportunity (window) study assessed the short-term effect of medroxyprogesterone acetate (MPA) alone versus MPA plus the histone deacetylase (HDAC) inhibitor entinostat on regulation of progesterone receptor (PR) in women with newly diagnosed endometrioid endometrial...

Cite
Duska LR, Filiaci VL, Walker JL, et al. A Surgical Window Trial Evaluating Medroxyprogesterone Acetate with or without Entinostat in Patients with Endometrial Cancer and Validation of Biomarkers of Cellular Response. Clin Cancer Res. 2021;27(10):2734-2741doi: 10.1158/1078-0432.CCR-20-4618.
Duska, L. R., Filiaci, V. L., Walker, J. L., Holman, L. L., Hill, E. K., Moore, R. G., Ring, K. L., Pearl, M. L., Muller, C. Y., Kushnir, C. L., Lankes, H. A., Samuelson, M. I., Carrick, K. S., Rajan, A., Rodgers, W. H., Kohn, E. C., Piekarz, R., & Leslie, K. K. (2021). A Surgical Window Trial Evaluating Medroxyprogesterone Acetate with or without Entinostat in Patients with Endometrial Cancer and Validation of Biomarkers of Cellular Response. Clinical cancer research : an official journal of the American Association for Cancer Research, 27(10), 2734-2741. https://doi.org/10.1158/1078-0432.CCR-20-4618
Duska, Linda R, et al. "A Surgical Window Trial Evaluating Medroxyprogesterone Acetate with or without Entinostat in Patients with Endometrial Cancer and Validation of Biomarkers of Cellular Response." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 27,10 (2021): 2734-2741. doi: https://doi.org/10.1158/1078-0432.CCR-20-4618
Duska LR, Filiaci VL, Walker JL, Holman LL, Hill EK, Moore RG, Ring KL, Pearl ML, Muller CY, Kushnir CL, Lankes HA, Samuelson MI, Carrick KS, Rajan A, Rodgers WH, Kohn EC, Piekarz R, Leslie KK. A Surgical Window Trial Evaluating Medroxyprogesterone Acetate with or without Entinostat in Patients with Endometrial Cancer and Validation of Biomarkers of Cellular Response. Clin Cancer Res. 2021 May 15;27(10):2734-2741. doi: 10.1158/1078-0432.CCR-20-4618. Epub 2021 Mar 25. PMID: 33766814; PMCID: PMC8127359.
Copy Download .nbib Format: NLM
Long-Term Outcomes of NRG Oncology/RTOG 0529: A Phase 2 Evaluation of Dose-Painted Intensity Modulated Radiation Therapy in Combination With 5-Fluorouracil and Mitomycin-C for the Reduction of Acute Morbidity in Anal Canal Cancer.

International journal of radiation oncology, biology, physics

Kachnic LA, Winter KA, Myerson RJ, Goodyear MD, Abitbol AA, Streeter OE, Augspurger ME, Schefter TE, Katz AW, Fisher BJ, Henke LE, Narayan S, Crane CH.
PMID: 34400269
Int J Radiat Oncol Biol Phys. 2022 Jan 01;112(1):146-157. doi: 10.1016/j.ijrobp.2021.08.008. Epub 2021 Aug 14.

PURPOSE: A multi-institutional phase 2 trial assessed long-term outcomes of dose-painted intensity modulated radiation therapy (IMRT) with 5-fluorouracil (5FU) and mitomycin-C (MMC) for anal canal cancer.METHODS AND MATERIALS: T2-4N0-3M0 anal cancers received 5FU (1000 mg/mRESULTS: Of 52 patients, 54%...

Cite
Kachnic LA, Winter KA, Myerson RJ, et al. Long-Term Outcomes of NRG Oncology/RTOG 0529: A Phase 2 Evaluation of Dose-Painted Intensity Modulated Radiation Therapy in Combination With 5-Fluorouracil and Mitomycin-C for the Reduction of Acute Morbidity in Anal Canal Cancer. Int J Radiat Oncol Biol Phys. 2021;112(1):146-157doi: 10.1016/j.ijrobp.2021.08.008.
Kachnic, L. A., Winter, K. A., Myerson, R. J., Goodyear, M. D., Abitbol, A. A., Streeter, O. E., Augspurger, M. E., Schefter, T. E., Katz, A. W., Fisher, B. J., Henke, L. E., Narayan, S., & Crane, C. H. (2022). Long-Term Outcomes of NRG Oncology/RTOG 0529: A Phase 2 Evaluation of Dose-Painted Intensity Modulated Radiation Therapy in Combination With 5-Fluorouracil and Mitomycin-C for the Reduction of Acute Morbidity in Anal Canal Cancer. International journal of radiation oncology, biology, physics, 112(1), 146-157. https://doi.org/10.1016/j.ijrobp.2021.08.008
Kachnic, Lisa A, et al. "Long-Term Outcomes of NRG Oncology/RTOG 0529: A Phase 2 Evaluation of Dose-Painted Intensity Modulated Radiation Therapy in Combination With 5-Fluorouracil and Mitomycin-C for the Reduction of Acute Morbidity in Anal Canal Cancer." International journal of radiation oncology, biology, physics vol. 112,1 (2022): 146-157. doi: https://doi.org/10.1016/j.ijrobp.2021.08.008
Kachnic LA, Winter KA, Myerson RJ, Goodyear MD, Abitbol AA, Streeter OE, Augspurger ME, Schefter TE, Katz AW, Fisher BJ, Henke LE, Narayan S, Crane CH. Long-Term Outcomes of NRG Oncology/RTOG 0529: A Phase 2 Evaluation of Dose-Painted Intensity Modulated Radiation Therapy in Combination With 5-Fluorouracil and Mitomycin-C for the Reduction of Acute Morbidity in Anal Canal Cancer. Int J Radiat Oncol Biol Phys. 2022 Jan 01;112(1):146-157. doi: 10.1016/j.ijrobp.2021.08.008. Epub 2021 Aug 14. PMID: 34400269.
Copy Download .nbib Format: NLM
Risk groups of laryngeal cancer treated with chemoradiation according to nomogram scores - A pooled analysis of RTOG 0129 and 0522.

Oral oncology

Awan MJ, Gittleman H, Barnholtz-Sloan J, Machtay M, Nguyen-Tan PF, Rosenthal DI, Schultz C, Huth BJ, Thorstad WL, Frank SJ, Kim H, Foote RL, Lango MN, Shenouda G, Suntharalingam M, Harris J, Zhang Q, Le QT, Yao M.
PMID: 33640577
Oral Oncol. 2021 May;116:105241. doi: 10.1016/j.oraloncology.2021.105241. Epub 2021 Feb 25.

OBJECTIVES: To develop nomograms predicting overall survival (OS), freedom from locoregional recurrence (FFLR), and freedom from distant metastasis (FFDM) for patients receiving chemoradiation for laryngeal squamous cell carcinoma (LSCC).MATERIAL AND METHODS: Clinical and treatment data for patients with LSCC...

Cite
Awan MJ, Gittleman H, Barnholtz-Sloan J, et al. Risk groups of laryngeal cancer treated with chemoradiation according to nomogram scores - A pooled analysis of RTOG 0129 and 0522. Oral Oncol. 2021;116:105241doi: 10.1016/j.oraloncology.2021.105241.
Awan, M. J., Gittleman, H., Barnholtz-Sloan, J., Machtay, M., Nguyen-Tan, P. F., Rosenthal, D. I., Schultz, C., Huth, B. J., Thorstad, W. L., Frank, S. J., Kim, H., Foote, R. L., Lango, M. N., Shenouda, G., Suntharalingam, M., Harris, J., Zhang, Q., Le, Q. T., Yao, M. (2021). Risk groups of laryngeal cancer treated with chemoradiation according to nomogram scores - A pooled analysis of RTOG 0129 and 0522. Oral oncology, 116105241. https://doi.org/10.1016/j.oraloncology.2021.105241
Awan, Musaddiq J, et al. "Risk groups of laryngeal cancer treated with chemoradiation according to nomogram scores - A pooled analysis of RTOG 0129 and 0522." Oral oncology vol. 116 (2021): 105241. doi: https://doi.org/10.1016/j.oraloncology.2021.105241
Awan MJ, Gittleman H, Barnholtz-Sloan J, Machtay M, Nguyen-Tan PF, Rosenthal DI, Schultz C, Huth BJ, Thorstad WL, Frank SJ, Kim H, Foote RL, Lango MN, Shenouda G, Suntharalingam M, Harris J, Zhang Q, Le QT, Yao M. Risk groups of laryngeal cancer treated with chemoradiation according to nomogram scores - A pooled analysis of RTOG 0129 and 0522. Oral Oncol. 2021 May;116:105241. doi: 10.1016/j.oraloncology.2021.105241. Epub 2021 Feb 25. PMID: 33640577; PMCID: PMC8144062.
Copy Download .nbib Format: NLM
Salvage Low Dose Rate Prostate Brachytherapy: Clinical Outcomes of a Phase II Trial for Local Recurrence after External Beam Radiotherapy (NRG Oncology/xxxx).

International journal of radiation oncology, biology, physics

Crook J, Rodgers JP, Pisansky TM, Trabulsi EJ, Amin MB, Bice W, Morton G, Murtha AD, Vigneault E, Helou J, Michalski JM, Roach M, Beyer D, Jani AB, Horwitz EM, Raben A, Pugh S, Sandler H.
PMID: 34740768
Int J Radiat Oncol Biol Phys. 2021 Nov 02; doi: 10.1016/j.ijrobp.2021.10.138. Epub 2021 Nov 02.

PURPOSE: We report efficacy of a prospective Phase II trial (YYYY) of salvage low dose rate (LDR) prostate brachytherapy (BT) for local failure (LF) after prior external beam radiotherapy (EBRT) with minimum 5- years' follow up.MATERIALS/METHODS: Eligible patients had...

Cite
Crook J, Rodgers JP, Pisansky TM, et al. Salvage Low Dose Rate Prostate Brachytherapy: Clinical Outcomes of a Phase II Trial for Local Recurrence after External Beam Radiotherapy (NRG Oncology/xxxx). Int J Radiat Oncol Biol Phys. 2021;doi: 10.1016/j.ijrobp.2021.10.138.
Crook, J., Rodgers, J. P., Pisansky, T. M., Trabulsi, E. J., Amin, M. B., Bice, W., Morton, G., Murtha, A. D., Vigneault, E., Helou, J., Michalski, J. M., Roach, M., Beyer, D., Jani, A. B., Horwitz, E. M., Raben, A., Pugh, S., & Sandler, H. (2021). Salvage Low Dose Rate Prostate Brachytherapy: Clinical Outcomes of a Phase II Trial for Local Recurrence after External Beam Radiotherapy (NRG Oncology/xxxx). International journal of radiation oncology, biology, physics, . https://doi.org/10.1016/j.ijrobp.2021.10.138
Crook, Juanita, et al. "Salvage Low Dose Rate Prostate Brachytherapy: Clinical Outcomes of a Phase II Trial for Local Recurrence after External Beam Radiotherapy (NRG Oncology/xxxx)." International journal of radiation oncology, biology, physics vol. (2021). doi: https://doi.org/10.1016/j.ijrobp.2021.10.138
Crook J, Rodgers JP, Pisansky TM, Trabulsi EJ, Amin MB, Bice W, Morton G, Murtha AD, Vigneault E, Helou J, Michalski JM, Roach M, Beyer D, Jani AB, Horwitz EM, Raben A, Pugh S, Sandler H. Salvage Low Dose Rate Prostate Brachytherapy: Clinical Outcomes of a Phase II Trial for Local Recurrence after External Beam Radiotherapy (NRG Oncology/xxxx). Int J Radiat Oncol Biol Phys. 2021 Nov 02; doi: 10.1016/j.ijrobp.2021.10.138. Epub 2021 Nov 02. PMID: 34740768.
Copy Download .nbib Format: NLM
Adding Short-Term Androgen Deprivation Therapy to Radiation Therapy in Men With Localized Prostate Cancer: Long-Term Update of the NRG/RTOG 9408 Randomized Clinical Trial.

International journal of radiation oncology, biology, physics

Jones CU, Pugh SL, Sandler HM, Chetner MP, Amin MB, Bruner DW, Zietman AL, Den RB, Leibenhaut MH, Longo JM, Bahary JP, Rosenthal SA, Souhami L, Michalski JM, Hartford AC, Amin PP, Roach M, Yee D, Efstathiou JA, Rodgers JP, Feng FY, Shipley WU.
PMID: 34481017
Int J Radiat Oncol Biol Phys. 2022 Feb 01;112(2):294-303. doi: 10.1016/j.ijrobp.2021.08.031. Epub 2021 Sep 01.

PURPOSE: For men with localized prostate cancer, NRG Oncology/Radiation Therapy Oncology Group (RTOG) 9408 demonstrated that adding short-term androgen deprivation therapy (ADT) to radiation therapy (RT) improved the primary endpoint of overall survival (OS) and improved disease-specific mortality (DSM),...

Cite
Jones CU, Pugh SL, Sandler HM, et al. Adding Short-Term Androgen Deprivation Therapy to Radiation Therapy in Men With Localized Prostate Cancer: Long-Term Update of the NRG/RTOG 9408 Randomized Clinical Trial. Int J Radiat Oncol Biol Phys. 2021;112(2):294-303doi: 10.1016/j.ijrobp.2021.08.031.
Jones, C. U., Pugh, S. L., Sandler, H. M., Chetner, M. P., Amin, M. B., Bruner, D. W., Zietman, A. L., Den, R. B., Leibenhaut, M. H., Longo, J. M., Bahary, J. P., Rosenthal, S. A., Souhami, L., Michalski, J. M., Hartford, A. C., Amin, P. P., Roach, M., Yee, D., Efstathiou, J. A., Rodgers, J. P., Feng, F. Y., & Shipley, W. U. (2022). Adding Short-Term Androgen Deprivation Therapy to Radiation Therapy in Men With Localized Prostate Cancer: Long-Term Update of the NRG/RTOG 9408 Randomized Clinical Trial. International journal of radiation oncology, biology, physics, 112(2), 294-303. https://doi.org/10.1016/j.ijrobp.2021.08.031
Jones, Christopher U, et al. "Adding Short-Term Androgen Deprivation Therapy to Radiation Therapy in Men With Localized Prostate Cancer: Long-Term Update of the NRG/RTOG 9408 Randomized Clinical Trial." International journal of radiation oncology, biology, physics vol. 112,2 (2022): 294-303. doi: https://doi.org/10.1016/j.ijrobp.2021.08.031
Jones CU, Pugh SL, Sandler HM, Chetner MP, Amin MB, Bruner DW, Zietman AL, Den RB, Leibenhaut MH, Longo JM, Bahary JP, Rosenthal SA, Souhami L, Michalski JM, Hartford AC, Amin PP, Roach M, Yee D, Efstathiou JA, Rodgers JP, Feng FY, Shipley WU. Adding Short-Term Androgen Deprivation Therapy to Radiation Therapy in Men With Localized Prostate Cancer: Long-Term Update of the NRG/RTOG 9408 Randomized Clinical Trial. Int J Radiat Oncol Biol Phys. 2022 Feb 01;112(2):294-303. doi: 10.1016/j.ijrobp.2021.08.031. Epub 2021 Sep 01. PMID: 34481017; PMCID: PMC8748315.
Copy Download .nbib Format: NLM
Showing 97 to 103 of 103 entries